Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Wen Shuo Wu, Yuh Min Chen, Chun Ming Tsai, Jen Fu Shih, Chao Hua Chiu, Kun Ta Chou, Shinn Liang Lai, Chieh Hung Wu, Yung Hung Luo, Chu Yun Huang, Yu Chin Lee, Reury Perng Perng, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective treatment for advanced non-small cell lung cancer. The objective of the present study was to compare the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation status was known. Pulmonary adenocarcinoma patients who began receiving gefitinib or erlotinib treatment from January 2005 to December 2010, and whose tumor EGFR mutation status had been determined, were included. Clinical data, type of treatment response and survival time data were collected. Of the 224 patients enrolled, 124 received gefitinib treatment and 100 received erlotinib treatment. Of these patients, 146 individuals had tumors with EGFR-activating mutations (exon 19 deletions and/point mutation of L858R in exon 21) and 78 did not. There was no difference in treatment response whether or not the patients had tumors with EGFR-activating mutations at the time they received gefitinib or erlotinib treatment. The median progression-free survival (PFS) of the gefitinib and erlotinib groups was 7.6 and 7.9 months, respectively (p=0.4731). PFS was significantly longer for patients without EGFR-activating mutations who received erlotinib treatment (n=48; median, 4.5 months) than for those who received gefitinib treatment (n=30; median, 2.3 months), with a hazard ratio of 0.58 (95% CI, 0.35-0.96; p=0.0339). Patients whose tumors had EGFR-activating mutations displayed no difference in PFS with either gefitinib (n=94; median, 10.5 months) or erlotinib treatment (n=52; median, 10.4 months). In conclusion, PFS showed no difference with either agent in patients whose tumors had EGFR-activating mutations, but was significantly longer in patients whose tumors did not have EGFR-activating mutations when receiving erlotinib treatment.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalExperimental and Therapeutic Medicine
Volume3
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Adenocarcinoma
Mutation
Disease-Free Survival
Neoplasms
Therapeutics
Exons
gefitinib
Erlotinib Hydrochloride
Sequence Deletion
Proxy
Point Mutation
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Survival

Keywords

  • Epidermal growth factor receptor
  • Non-small cell lung cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology (miscellaneous)
  • Cancer Research

Cite this

Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. / Wu, Wen Shuo; Chen, Yuh Min; Tsai, Chun Ming; Shih, Jen Fu; Chiu, Chao Hua; Chou, Kun Ta; Lai, Shinn Liang; Wu, Chieh Hung; Luo, Yung Hung; Huang, Chu Yun; Lee, Yu Chin ; Perng, Reury Perng; Whang-Peng, Jacqueline.

In: Experimental and Therapeutic Medicine, Vol. 3, No. 2, 02.2012, p. 207-213.

Research output: Contribution to journalArticle

Wu, Wen Shuo ; Chen, Yuh Min ; Tsai, Chun Ming ; Shih, Jen Fu ; Chiu, Chao Hua ; Chou, Kun Ta ; Lai, Shinn Liang ; Wu, Chieh Hung ; Luo, Yung Hung ; Huang, Chu Yun ; Lee, Yu Chin ; Perng, Reury Perng ; Whang-Peng, Jacqueline. / Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. In: Experimental and Therapeutic Medicine. 2012 ; Vol. 3, No. 2. pp. 207-213.
@article{c16a4913f6d14eb487df6bf7cf13ce69,
title = "Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations",
abstract = "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective treatment for advanced non-small cell lung cancer. The objective of the present study was to compare the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation status was known. Pulmonary adenocarcinoma patients who began receiving gefitinib or erlotinib treatment from January 2005 to December 2010, and whose tumor EGFR mutation status had been determined, were included. Clinical data, type of treatment response and survival time data were collected. Of the 224 patients enrolled, 124 received gefitinib treatment and 100 received erlotinib treatment. Of these patients, 146 individuals had tumors with EGFR-activating mutations (exon 19 deletions and/point mutation of L858R in exon 21) and 78 did not. There was no difference in treatment response whether or not the patients had tumors with EGFR-activating mutations at the time they received gefitinib or erlotinib treatment. The median progression-free survival (PFS) of the gefitinib and erlotinib groups was 7.6 and 7.9 months, respectively (p=0.4731). PFS was significantly longer for patients without EGFR-activating mutations who received erlotinib treatment (n=48; median, 4.5 months) than for those who received gefitinib treatment (n=30; median, 2.3 months), with a hazard ratio of 0.58 (95{\%} CI, 0.35-0.96; p=0.0339). Patients whose tumors had EGFR-activating mutations displayed no difference in PFS with either gefitinib (n=94; median, 10.5 months) or erlotinib treatment (n=52; median, 10.4 months). In conclusion, PFS showed no difference with either agent in patients whose tumors had EGFR-activating mutations, but was significantly longer in patients whose tumors did not have EGFR-activating mutations when receiving erlotinib treatment.",
keywords = "Epidermal growth factor receptor, Non-small cell lung cancer, Tyrosine kinase inhibitors",
author = "Wu, {Wen Shuo} and Chen, {Yuh Min} and Tsai, {Chun Ming} and Shih, {Jen Fu} and Chiu, {Chao Hua} and Chou, {Kun Ta} and Lai, {Shinn Liang} and Wu, {Chieh Hung} and Luo, {Yung Hung} and Huang, {Chu Yun} and Lee, {Yu Chin} and Perng, {Reury Perng} and Jacqueline Whang-Peng",
year = "2012",
month = "2",
doi = "10.3892/etm.2011.383",
language = "English",
volume = "3",
pages = "207--213",
journal = "Experimental and Therapeutic Medicine",
issn = "1792-0981",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

AU - Wu, Wen Shuo

AU - Chen, Yuh Min

AU - Tsai, Chun Ming

AU - Shih, Jen Fu

AU - Chiu, Chao Hua

AU - Chou, Kun Ta

AU - Lai, Shinn Liang

AU - Wu, Chieh Hung

AU - Luo, Yung Hung

AU - Huang, Chu Yun

AU - Lee, Yu Chin

AU - Perng, Reury Perng

AU - Whang-Peng, Jacqueline

PY - 2012/2

Y1 - 2012/2

N2 - Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective treatment for advanced non-small cell lung cancer. The objective of the present study was to compare the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation status was known. Pulmonary adenocarcinoma patients who began receiving gefitinib or erlotinib treatment from January 2005 to December 2010, and whose tumor EGFR mutation status had been determined, were included. Clinical data, type of treatment response and survival time data were collected. Of the 224 patients enrolled, 124 received gefitinib treatment and 100 received erlotinib treatment. Of these patients, 146 individuals had tumors with EGFR-activating mutations (exon 19 deletions and/point mutation of L858R in exon 21) and 78 did not. There was no difference in treatment response whether or not the patients had tumors with EGFR-activating mutations at the time they received gefitinib or erlotinib treatment. The median progression-free survival (PFS) of the gefitinib and erlotinib groups was 7.6 and 7.9 months, respectively (p=0.4731). PFS was significantly longer for patients without EGFR-activating mutations who received erlotinib treatment (n=48; median, 4.5 months) than for those who received gefitinib treatment (n=30; median, 2.3 months), with a hazard ratio of 0.58 (95% CI, 0.35-0.96; p=0.0339). Patients whose tumors had EGFR-activating mutations displayed no difference in PFS with either gefitinib (n=94; median, 10.5 months) or erlotinib treatment (n=52; median, 10.4 months). In conclusion, PFS showed no difference with either agent in patients whose tumors had EGFR-activating mutations, but was significantly longer in patients whose tumors did not have EGFR-activating mutations when receiving erlotinib treatment.

AB - Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective treatment for advanced non-small cell lung cancer. The objective of the present study was to compare the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation status was known. Pulmonary adenocarcinoma patients who began receiving gefitinib or erlotinib treatment from January 2005 to December 2010, and whose tumor EGFR mutation status had been determined, were included. Clinical data, type of treatment response and survival time data were collected. Of the 224 patients enrolled, 124 received gefitinib treatment and 100 received erlotinib treatment. Of these patients, 146 individuals had tumors with EGFR-activating mutations (exon 19 deletions and/point mutation of L858R in exon 21) and 78 did not. There was no difference in treatment response whether or not the patients had tumors with EGFR-activating mutations at the time they received gefitinib or erlotinib treatment. The median progression-free survival (PFS) of the gefitinib and erlotinib groups was 7.6 and 7.9 months, respectively (p=0.4731). PFS was significantly longer for patients without EGFR-activating mutations who received erlotinib treatment (n=48; median, 4.5 months) than for those who received gefitinib treatment (n=30; median, 2.3 months), with a hazard ratio of 0.58 (95% CI, 0.35-0.96; p=0.0339). Patients whose tumors had EGFR-activating mutations displayed no difference in PFS with either gefitinib (n=94; median, 10.5 months) or erlotinib treatment (n=52; median, 10.4 months). In conclusion, PFS showed no difference with either agent in patients whose tumors had EGFR-activating mutations, but was significantly longer in patients whose tumors did not have EGFR-activating mutations when receiving erlotinib treatment.

KW - Epidermal growth factor receptor

KW - Non-small cell lung cancer

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84855383474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855383474&partnerID=8YFLogxK

U2 - 10.3892/etm.2011.383

DO - 10.3892/etm.2011.383

M3 - Article

VL - 3

SP - 207

EP - 213

JO - Experimental and Therapeutic Medicine

JF - Experimental and Therapeutic Medicine

SN - 1792-0981

IS - 2

ER -